Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist - PubMed (original) (raw)
. 2003 Oct 15;102(8):2728-30.
doi: 10.1182/blood-2003-02-0663. Epub 2003 Jul 10.
Affiliations
- PMID: 12855591
- DOI: 10.1182/blood-2003-02-0663
Free article
Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist
W Conrad Liles et al. Blood. 2003.
Free article
Abstract
Stromal cell-derived factor 1 (SDF1/CXCL12) and its cognate receptor, CXCR4, play key regulatory roles in CD34+ cell trafficking. We investigated whether AMD3100, a selective CXCR4 antagonist, could mobilize hematopoietic progenitor cells from marrow to peripheral blood in healthy human volunteers. Initially, 10 persons each received a single dose of AMD3100 (80 microsubcutaneously), which induced rapid, generalized leukocytosis associated with an increase in peripheral blood CD34+ cells, representing pluripotent hematopoietic progenitors by in vitro colony-forming unit assays, from 3.8 +/- 0.5/microL to 20.7 +/- 3.5/microL at 6 hours. Subsequent dose-response studies showed a maximum increase in circulating CD34+ cells from 2.6 +/- 0.3/microL to 40.4 +/- 3.4/microL at 9 hours after 240 micro/kg AMD3100. Serial administration of AMD3100 (80 microg/kg/d for 3 days) resulted in consistent, reversible increases in peripheral blood CD34+ cells. AMD3100 was well tolerated and caused only mild, transient toxicity. These findings suggest potential clinical application of AMD3100 for CD34+ cell mobilization and collection for hematopoietic stem cell transplantation.
Similar articles
- Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma.
Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, Badel K, Calandra G, DiPersio JF. Devine SM, et al. J Clin Oncol. 2004 Mar 15;22(6):1095-102. doi: 10.1200/JCO.2004.07.131. J Clin Oncol. 2004. PMID: 15020611 Clinical Trial. - Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist.
Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA, Liles WC, Li X, Graham-Evans B, Campbell TB, Calandra G, Bridger G, Dale DC, Srour EF. Broxmeyer HE, et al. J Exp Med. 2005 Apr 18;201(8):1307-18. doi: 10.1084/jem.20041385. J Exp Med. 2005. PMID: 15837815 Free PMC article. - Effective mobilization of hematopoietic progenitor cells in G-CSF mobilization defective CD26-/- mice through AMD3100-induced disruption of the CXCL12-CXCR4 axis.
Paganessi LA, Walker AL, Tan LL, Holmes I, Rich E, Fung HC, Christopherson KW 2nd. Paganessi LA, et al. Exp Hematol. 2011 Mar;39(3):384-90. doi: 10.1016/j.exphem.2010.12.003. Epub 2010 Dec 17. Exp Hematol. 2011. PMID: 21168468 Free PMC article. - Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.
Uy GL, Rettig MP, Cashen AF. Uy GL, et al. Expert Opin Biol Ther. 2008 Nov;8(11):1797-804. doi: 10.1517/14712598.8.11.1797. Expert Opin Biol Ther. 2008. PMID: 18847313 Review. - Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.
De Clercq E. De Clercq E. Pharmacol Ther. 2010 Dec;128(3):509-18. doi: 10.1016/j.pharmthera.2010.08.009. Epub 2010 Sep 15. Pharmacol Ther. 2010. PMID: 20826182 Review.
Cited by
- CCR2 cooperativity promotes hematopoietic stem cell homing to the bone marrow.
Hurwitz SN, Kobulsky DR, Jung SK, Chia JJ, Butler JM, Kurre P. Hurwitz SN, et al. Sci Adv. 2024 Sep 20;10(38):eadq1476. doi: 10.1126/sciadv.adq1476. Epub 2024 Sep 18. Sci Adv. 2024. PMID: 39292787 Free PMC article. - Trafficking circuit of CD8+ T cells between the intestine and bone marrow governs antitumour immunity.
Shi RY, Zhou N, Xuan L, Jiang ZH, Xia J, Zhu JM, Chen KM, Zhou GL, Yu GP, Zhang J, Huang C, Liang AB, Liang KW, Zhang H, Chen JF, Zhang D, Zhong Y, Liu QF, Chen GQ, Duan CW. Shi RY, et al. Nat Cell Biol. 2024 Aug;26(8):1346-1358. doi: 10.1038/s41556-024-01462-3. Epub 2024 Jul 22. Nat Cell Biol. 2024. PMID: 39039181 - Targeting immune cell recruitment in atherosclerosis.
Döring Y, van der Vorst EPC, Weber C. Döring Y, et al. Nat Rev Cardiol. 2024 Apr 25. doi: 10.1038/s41569-024-01023-z. Online ahead of print. Nat Rev Cardiol. 2024. PMID: 38664575 Review. - Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group.
Fazio F, Passucci M, Micozzi J, Di Landro F, Fianchi L, Za T, Manieri VM, Annibali O, Cupelli L, Bongarzoni V, Gentili S, De Padua L, Crisanti E, Garzia MG, Rago A, Piciocchi A, Mengarelli A, Morè S, De Stefano V, Bafti MS, Martelli M, Petrucci MT. Fazio F, et al. Bone Marrow Transplant. 2024 Jun;59(6):896-898. doi: 10.1038/s41409-024-02260-z. Epub 2024 Mar 9. Bone Marrow Transplant. 2024. PMID: 38461292 Free PMC article. No abstract available. - Homing and Engraftment of Hematopoietic Stem Cells Following Transplantation: A Pre-Clinical Perspective.
Hasan T, Pasala AR, Hassan D, Hanotaux J, Allan DS, Maganti HB. Hasan T, et al. Curr Oncol. 2024 Jan 23;31(2):603-616. doi: 10.3390/curroncol31020044. Curr Oncol. 2024. PMID: 38392038 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical